Key result
Silymarin nanoparticles reduce doxorubicin-induced myocardial injury and inflammatory markers more effectively than standard silymarin.
Why the study?
Do silymarin and silymarin nanoparticles ameliorate doxorubicin-induced cardiac toxicity, oxidative stress, apoptosis, and inflammation in rats?
Do silymarin and silymarin nanoparticles ameliorate doxorubicin-induced cardiac toxicity, oxidative stress, apoptosis, and inflammation in rats?
In a rat model, silymarin nanoparticles provided superior cardioprotection against doxorubicin-induced cardiotoxicity compared to conventional silymarin by attenuating oxidative stress, inflammation, and apoptosis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for silymarin nanoparticles in rat doxorubicin cardiotoxicity; should not change clinical practice.
Doxorubicin is one of the most important chemotherapies, it treats many types of cancers but it has toxic effects on heart tissue as it causes oxidative stress, apoptosis and inflammation which limits the therapeutic usage of doxorubicin as an anticancer drug. Herbal extracts as silymarin have a cardioprotective effect and silymarin nanoparticles (SiNPs) improve the poor bioavailability of silymarin. To assess a comparison between the possible protective effect of Silymarin and its nanoparticles on doxorubicin induced cardiotoxicity and to assess the possible mechanisms. Forty-eight rats were divided into four groups: Control group, Doxorubicin group (Dx-group), Silymarin treated group (s-group) and Nanosilymarin treated group (SiNPs-group). Measurement of cardiac enzymes (CK, LDH, AST and ALT), malondialdehyde (MDA) and Glutathion (GSH) in the heart tissue, and histological approaches by light microscope, transmission electron microscope and immunohistochemical study for activated -caspase 3 and IL-6 were done. Dx-group showed significant (p < 0.05) increase in cardiac enzymes levels, significant (p < 0.05) increase in MDA levels in cardiomyocytes and significant (p < 0.05) decrease in GSH level compared to control group, also strong immunopositivity of IL-6 (p < 0.05) and activated-caspase 3(p < 0.01) and histological degenerative changes in the heart tissue. These changes improved in S-group but SiNPs-group showed better findings. Doxorubicin had an apparent damaging effect on cardiac tissue structure by different mechanisms as oxidative stress, apoptosis and inflammation and co-administration with natural compounds as silymarin improves the toxic effect of doxorubicin but silymarin nanoparticles give better effect than silymarin which is suggestive of improved bioavailability and targeted delivery.
No takes yet. Share an insight, caveat, or question.
Mohammed et al. (2026) studied Doxorubicin-induced cardiac toxicity (n=48). Silymarin and silymarin nanoparticles (SiNPs) vs. Doxorubicin alone and untreated control was evaluated on Cardiac enzymes (CK, LDH, AST, ALT), myocardial oxidative stress markers (MDA, GSH), immunohistochemistry (activated-caspase 3, IL-6), and cardiac histology (p=<0.05). Silymarin nanoparticles improved doxorubicin-induced elevations in cardiac enzymes, MDA, IL-6, and activated-caspase 3 more effectively than silymarin.
Synapse has enriched 10 related papers. Consider them for comparative context: